The company purchased Tute in a stock-based transaction that closed last month.
The newly minted company offers panel, whole-genome and whole exome sequencing, as well as bioinformatics analysis and reporting services to oncologists.
The app lets physicians use their mobile phones to access clinical trial matching capabilities from the broader GenoSpace portfolio.
Frameshift plans to commercialize two applications: one for data quality control and a second for identifying mutations in rare and Mendelian disorders.
The partners have committed to analyzing coding mutations, driver non-coding mutations, and structural variations across tumor types for the project.
Additions to the company's portfolio in the last two years provide a broader footing for clinical NGS analysis and reporting workflows.
Researchers participating in ORIEN's Avatar program can use the platform to manage, share, integrate, and analyze molecular data from consenting patients.
The platform features a more comprehensive list of pipelines, simplifies data movement and flow, and reduces analysis times.
HUG's genetic medicine arm will use Saphetor's software and variant knowledgebase in clinical projects focused on developmental and neurological disorders.
Having sequenced close to 15,000 samples, the project is now taking steps toward integrating results fully into patient medical records.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.
A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.
Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.